2024-11-08T15:29:11-06:00 2023-12-31 580692043 MAULDIN & JENKINS LLC 200 GALLERIA PKWY SE STE 1700 ATLANTA GA 303395946 990 2023-01-01 822120760 ODYLIA THERAPEUTICS INC ODYL 7708429741 830 GLENWOOD AVE SE 510-323 ATLANTA GA 30316 ASHLEY WINSLOW CEO/CSO 7708429741 2024-11-08 1 1 MELISSA SEWARD P02145103 7709558600 2024-11-08 2023 2024-10-15 13:58:12Z X ASHLEY WINSLOW 830 GLENWOOD AVE SE 510-323 ATLANTA GA 30316 570773 0 X WWW.ODYLIA.ORG X 2017 DE ODLYIA UTILIZES A UNIQUE, NON-PROFIT MODEL TO ACCELERATE THE DEVELOPMENT OF GENE THERAPIES FROM PEOPLE WITH RARE DISEASE, CHANGING THE WAY TREATMENTS ARE BROUGHT FROM THE LAB TO THE CLINIC. 6 6 4 6 0 0 976484 289283 107361 241089 14556 40401 0 0 1098401 570773 0 0 0 0 645547 537882 0 0 106354 220926 329354 866473 867236 231928 -296463 10021651 9688644 95757 41336 9925894 9647308 X ODLYIA'S MISSION IS TO FACILITATE THE RESEARCH OF GENETICS, GENETIC THERAPIES AND SAFE AND EFFECTIVE TREATMENTS THAT ADDRESS RARE AND ULTRA-ARE DISEASES, INCLUDING TO (I) RESEARCH AND DEVELOP METHODOLOGIES FOR MORE EFFECTIVE AND EFFICIENT DEVELOPMENT OF THERAPIES AND TREATMENTS OF RARE AND ULTRA-RARE DISEASES INCLUDING, BUT NOT LIMITED TO, THE CONDUCT AND OVERSIGHT OF CLINICAL TRIALS, (II) COMPILE AND DISSEMINATE SCIENTIFIC LITERATURE THAT PROMOTES AND ATTRACTS RESOURCES FOR RESEARCH AND THE DEVELOPMENT OF THERAPIES AND TREATMENTS THAT ADDRESS RARE AND ULTRA-RARE DISEASES, (III) DEVELOP BEST PRACTICES IN THE FIELD OF RESEARCH AND THE DEVELOPMENT OF TREATMENTS OF RARE AND ULTRA-RARE DISEASES AND (IV) ENGAGE IN AND CARRY ON ANY SUCH OTHER ACTIVITIES IN FURTHERANCE OF SUCH PURPOSES AS NONPROFIT CORPORATIONS ORGANIZED UNDER THE DELAWARE GENERAL CORPORATION LAW MAY CONDUCT, BUT ONLY TO THE EXTENT THAT SUCH ACTIVITIES SHALL BE PERMITTED UNDER SECTION 50L(C)(3) OF THE CODE. 0 0 636178 241089 ADVANCING DRUG DEVELOPMENT FOR RARE DISEASES. ODYLIA'S TOP THREE PROGRAMS ARE RPGRIP1, USH1C, AND BRYDGE SOLUTIONS. 636178 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 5 0 1 4 1 0 0 0 0 0 0 0 0 0 0 0 0 X 6 6 1 0 0 0 1 1 0 1 1 0 0 1 1 1 1 1 1 1 0 0 MA X X THE ORGANIZATION 7708429741 830 GLENWOOD AVE SE 510-323 ATLANTA GA 30316 ASHLEY WINSLOW CEO/CSO 40.00 X 230695 0 0 JENNY KLEIN MANAGER OF OPERATIONS & PROGRAM MANAGEMENT 40.00 X 109099 0 0 SCOTT DORFMAN BOARD CHAIRMAN/TREASURER 6.00 X X 0 0 0 SUSIE TROTOCHAUD SECRETARY 3.00 X X 0 0 0 KHANDAN BARADARAN BOARD MEMBER 1.00 X 0 0 0 BRIAN FENTON BOARD MEMBER 1.00 X 0 0 0 MATTHEW PLETCHER BOARD MEMBER 1.00 X 0 0 0 LUK VANDENBERGH BOARD MEMBER 1.00 X 0 0 0 GREG ROBINSON BOARD MEMBER 1.00 X 0 0 0 339794 0 0 1 0 1 0 0 289283 289283 SERVICE FEE REVENUE 900099 241089 241089 241089 40401 40401 570773 241089 0 40401 X 230695 166788 31752 32155 250506 181110 34479 34917 5230 3781 720 729 15338 11089 2111 2138 36113 26628 4475 5010 10939 10939 225890 219953 1848 4089 59712 20709 20486 18517 5218 110 5048 60 4861 2952 1909 11150 4343 5560 1247 11584 1667 4334 5583 867236 636178 124704 106354 148526 108152 64034 14000 3515 3515 1119610 748943 8750000 8750000 10021651 9688644 95757 41336 95757 41336 X 9925894 9647308 9925894 9647308 10021651 9688644 -296463 17877 0 X X 1 X 0 1 0 X 13576 14111 233084 976484 289283 1526538 13576 14111 233084 976484 289283 1526538 812210 714328 12271 18882 10396 14556 40401 96506 225 225 1623269 1725760 0.44010 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER INCOME - 2020 AMOUNT: $ 225. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED X 0 0 0 0 0 0 0 0 0 ASHLEY WINSLOW CEO/CSO 230695 0 0 0 0 0 0 0 0 0 230695 0 0 0 FORM 990, PART VI, SECTION A, LINE 2 SCOTT DORFMAN AND SUSIE TROTOCHAUD HAVE A FAMILIAL RELATIONSHIP. FORM 990, PART VI, SECTION A, LINE 6 THE ORGANIZATION HAS TWO STATUTORY MEMBERS, THE MASSACHUSETTS EYE AND EAR INFIRMARY AND USHER 2020 FOUNDATION, INC. FORM 990, PART VI, SECTION A, LINE 7A THE ORGANIZATION'S MEMBERS CAN ELECT OR APPOINT 2 DIRECTORS OF THE GOVERNING BODY. FORM 990, PART VI, SECTION B, LINE 11B THE BOARD OF DIRECTORS ARE PROVIDED WITH FORM 990 FOR THE OPPORTUNITY TO PROVIDE COMMENTS AND QUESTIONS, WITHIN TWO WEEKS OF DOCUMENT PROVISION, TO ENSURE THERE IS TIME FOR DISCUSSION BEFORE SUBMISSION. FORM 990, PART VI, SECTION B, LINE 12C BOARD MEMBERS AND STAFF ARE ASKED TO DISCLOSE CONFLICT OF INTEREST THROUGH A FORM THAT IS FILLED OUT. ANY CHANGES IN CONFLICT OF INTERESTS ARE ASKED TO BE UPDATED WHEN CHANGES OCCUR, AND AT LEAST ANNUALLY. FORM 990, PART VI, SECTION B, LINE 15A DISCUSSED WITH INDUSTRY EXPERTS AND INDEPENDENT BOARD MEMBERS TO DETERMINE COMPENSATION. FORM 990, PART VI, SECTION C, LINE 19 DOCUMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G RPGRIP1: PROGRAM SERVICE EXPENSES 57,750. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 57,750. HR ADMINISTRATION: PROGRAM SERVICE EXPENSES 9,540. MANAGEMENT AND GENERAL EXPENSES 1,816. FUNDRAISING EXPENSES 1,839. TOTAL EXPENSES 13,195. CONTRACT SERVICES: PROGRAM SERVICE EXPENSES 152,663. MANAGEMENT AND GENERAL EXPENSES 32. FUNDRAISING EXPENSES 2,250. TOTAL EXPENSES 154,945. PART XII, LINE 2C THE ORGANIZATION SELECTED A NEW INDEPENDENT ACCOUNTING FIRM TO CONDUCT THEIR REVIEW FOR THE YEAR ENDED DECEMBER 31, 2023.